Sterile Liquid Formulation Development Service
CD BioGlyco provides a specialized sterile liquid formulation development service that addresses the unique challenges of maintaining drug potency while ensuring absolute sterility. Sterile liquids must not only be free of viable microorganisms but must also meet stringent requirements for pyrogenicity, particulate matter, and physiological compatibility. Our scientific team leverages deep expertise in biopharmaceutical characterization to design liquid matrices that protect against oxidative, hydrolytic, and photolytic degradation. We focus on the delicate balance of pH optimization, tonicity adjustment, and the strategic use of stabilizers to ensure that even the most fragile molecules, such as monoclonal antibodies and oligonucleotides, remain bioactive throughout their shelf life. By integrating quality by design (QbD) principles, we develop formulations that are inherently robust and optimized for large-scale aseptic manufacturing.
We utilize a state-of-the-art technological suite to overcome the barriers to sterile liquid stability:
We utilize advanced computational tools to predict the interaction between the formulation and primary packaging materials, particularly for Blow-Fill-Seal (BFS) and glass vial systems, preventing leaching and sorption issues.
For poorly soluble sterile liquids, we engineer NLCs and nano-emulsions that provide high loading capacity and superior stability compared to traditional micellar solutions.
When liquid stability is insufficient for long-term storage, we develop optimized freeze-drying protocols that ensure rapid reconstitution and minimal loss of activity.
Utilizing high-throughput forced degradation studies to identify the ideal combination of cryoprotectants, antioxidants, and chelating agents for biologics.
Evaluating membrane compatibility and drug binding during sterile filtration processes to ensure 100% recovery of the active pharmaceutical ingredient (API).
The sterile liquid formulation development service encompasses a wide array of therapeutic categories and delivery formats. We are particularly adept at developing small volume parenterals (SVP) and large volume parenterals (LVP), ensuring that each product is tailored to its intended route of administration. Our expertise also extends to ophthalmic sterile drops, where we focus on minimizing irritation through precise osmotic and pH control.
Our specialized scope includes:
We initiate the process with a comprehensive feasibility and risk assessment, where we critically evaluate the API's key physicochemical properties, including its pKa, solubility-pH profile, and sensitivity to thermal and oxidative stress. This foundational analysis allows us to de-risk development by identifying the most viable and gentle sterilization route (e.g., autoclaving vs. aseptic filtration) early on, ensuring the method selected is compatible with the molecule's stability profile.
Our team then focuses on pre-formulation and achieving target solubility. We systematically screen and utilize pharmaceutically acceptable cosolvents, complexing agents (e.g., cyclodextrins), or surfactants to solubilize the API. The goal is to achieve the required therapeutic concentration while maintaining a stable, clear, and isotonic solution that is suitable for parenteral administration, paying close attention to solution clarity and compatibility with common packaging systems.
Through an iterative, QbD approach, we design multiple prototype formulations. These iterations systematically vary critical factors such as buffer species, pH, ionic strength, and antioxidant levels. Each prototype is subjected to accelerated stability studies (e.g., ICH conditions) to identify the most robust candidate formulation that maintains chemical and physical stability over the intended shelf life.
A critical stage involves developing and comparing sterilization methodologies. We rigorously evaluate terminal sterilization (autoclaving) against aseptic filtration to determine which method most effectively preserves API integrity while still achieving the necessary sterility assurance level. This ensures the final process effectively eliminates bioburden without degrading the product.
The lead formulation then transitions to scale-up and fill-finish simulation. We transfer the process to pilot-scale equipment, meticulously optimizing critical process parameters (CPPs) such as mixing shear, time, temperature, and filling speeds. This phase is crucial for ensuring content uniformity, preventing air entrapment or degradation, and demonstrating that the process is scalable and robust.
Finally, the scaled-up batches undergo rigorous analytical validation and quality control testing. This includes testing for sterility, bacterial endotoxins, sub-visible particulate matter, assay, and impurities in strict accordance with relevant pharmacopeial standards, ensuring the final product meets all specifications for safety, quality, and efficacy.
Journal: Nucleic Acid Therapeutics
DOI: 10.1089/nat.2022.0073
IF: 4.7
Published: 2023
Results: In this comprehensive article, DeCollibus et al., representing the European Pharma Oligonucleotide Consortium (EPOC), provide a detailed analysis and set of recommendations for the terminal sterilization (TS) of oligonucleotide drug products. The authors highlight the clear regulatory preference for TS due to its superior sterility assurance compared to aseptic processing, while acknowledging that thermal sensitivity has led the industry to predominantly rely on membrane filtration for current marketed oligonucleotides. They meticulously review key regulatory guidelines, particularly the European Medicines Agency's 2019 directive, which provides a decision tree for sterilization method selection. The paper outlines a systematic development paradigm for assessing TS feasibility, emphasizing the critical need for formulation optimization, such as using phosphate buffers to maintain pH stability, and a thorough understanding of oligonucleotide degradation pathways under thermal stress. Further considerations include autoclave cycle development, container closure integrity under pressure, and managing impurity profiles. The authors conclude that while TS is not suitable for all oligonucleotide subclasses (e.g., siRNAs), it may be viable for more stable molecules like antisense oligonucleotides with a rigorous, science-based evaluation and early engagement with regulators.
Oncology Injectables
Developing highly stable, concentrated sterile liquids for chemotherapy and targeted immunotherapy where dosage precision is critical for efficacy and safety.
Gene & Cell Therapy Delivery
Engineering specialized sterile vehicles for the delivery of viral vectors and modified cells, ensuring survival and potency through the delivery device.
Pediatric Injectables
Designing low-volume, high-precision sterile doses tailored to the unique physiological requirements of neonatal and pediatric patients to ensure maximum safety.
Vaccine Formulation
Stabilizing antigens and adjuvants in sterile liquid or lyophilized formats to ensure potency across the cold chain and facilitate global distribution.
Expertise in Fragile Biologics
We specialize in the "hard-to-stabilize" segment of biologics. Our specialized stabilizer blends can reduce protein aggregation by up to 85% compared to standard saline formulations.
Tailored Sterilization Protocols
Rather than a one-size-fits-all approach, we customize the sterilization process to the molecule's thermal sensitivity, ensuring the highest safety profile without degrading the active drug.
Primary Packaging Compatibility
We perform exhaustive extractable and leachable (E&L) studies to ensure that the sterile liquid does not react with the glass, stopper, or plastic container, maintaining long-term purity.
Robust Technology Transfer
Our development reports are exceptionally detailed, including all critical process parameters (CPPs) to ensure that your CDMO can manufacture the product without expensive trial-and-error.
CD BioGlyco's expertise in oligonucleotide stabilization was a game-changer for our phase I program. They delivered a sterile liquid that remained stable at 4°C for over 18 months.
— By Dr. J. R, Director of Biologics
The transition of our lead candidate to a BFS format was seamless thanks to CD BioGlyco. Their compatibility modeling saved us months of stability testing and prevented polymer-drug interactions.
— By Manager of Clinical Development
The endotoxin control and particulate matter profiling provided by CD BioGlyco were world-class. Their documentation made our regulatory submission incredibly straightforward.
— By Senior V.P. of R&D
To provide a holistic approach to precision drug delivery, we offer specialized RNA delivery platforms:
Efficient liquid-phase conjugation for high-throughput RNA delivery optimization.
Precise, column-based synthesis for highly purified and characterized RNA conjugates.
Utilizing GalNAc-functionalized lipids to enhance the hepatic targeting of lipid nanoparticles (LNPs).
Rapid and site-specific ligation techniques for complex oligonucleotide architectures.
CD BioGlyco stands at the forefront of sterile liquid formulation development, providing the scientific rigor and technical innovation required to bring sophisticated parenterals and ophthalmics to market. Our commitment to stability, sterility, and scalability ensures that your therapeutic molecules are transformed into safe and effective products. To discuss your sterile liquid project or to learn more about our development capabilities, please contact us.
Reference
